Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7442 PK Comparability Study
NCT05166421Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity at Day 361, Area Under the Serum Concentration-time Curve From Day Zero to the Last Measurable Concentration at Day 361 and 1 more. Started Nov 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05166421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166421.